Genetic manipulation of vein grafts

Current Opinion in Cardiology

Volumn 12, Issue 6, 1997, Pages 522-527

  Mann, Michael J ^a   Dzau, Victor J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS SURGERY; DISEASE COURSE; GENETIC ENGINEERING; GENETIC MANIPULATION; GRAFT FAILURE; HUMAN; MOLECULAR BIOLOGY; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; REVIEW; VEIN GRAFT;

EID: 0030772918     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199711000-00004     Document Type: Review

References (23)

1. Campeau LM, Enjalbert J, Lesperance MC, Bourassa P, Kwiterowich S, Wacholder A, Sniderman A: The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med 1984, 311:1329-1334.
2. Grondin CM, Campeau L, Thornton JC, Engle JC, Cross FS, Schreiber H: Coronary artery bypass grafting with saphenous vein. Circ 1989, 79:I-24-I-29.
3. Brewster DC, LaSalle AJ, Robinson JG, Strayhorn EC, Darling CR: Factors affecting patency of femoropopliteal bypass grafts. Surg Gynecol Obstet 1983, 157:437-442.
4. Lytle BW, Cosgrove DM, Saltus GL, Tayloy PC, Loop D: Multivessel coronary revascularization without saphenous vein graft: long-term results of bilateral internal mammary bypass. Ann Thoracic Surg 1983, 36:540-544.
5. Goldman S, Copelan J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Rend R, Chesler E, Sako Y: Saphenous vein graft patency 1 year after coronary artery bypass surgery and of antiplatelet therapy. Circ 1989, 80:1190-1197.
6. Cox JL, Chaisson DA, Gotleib AI: Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis. Prog Cardiovasc Dis 1991, 34:45-68.
7. Clowes AW, Reidy MA: Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia. J Vasc Surg 1991, 13:885-890.
8. Zwolak RM, Adams MC, Clowes AW: Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg 1987, 5:126-136.
9. Tanaka H, Sukhova GK, Swanson SJ, Clinton SK, Ganz P, Cybulsky MI, Libby P: Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circ 1993, 88:1788-1803.
10. Ku DD, Caulfield JB, Kirklin JK: Endothelium-dependent responses in long-term human coronary artery bypass grafts. Circ 1991, 83:402-411.
11. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao P, Cooke JP, Kaneda Y, Dzau VJ: Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA 1995, 92:4502-4506.
12. Mann MJ, Gibbons GH, Tsao PS, von der Leyen HE, Buitrago R, Kernoff R, Cooke JP, Dzau VJ: Cell cycle inhibition preserves endothelial function in genetically engineered vein grafts. J Clin Invest 1997, 99:1295-1301.
13. Bauters C, de Groote P, Adamantidis M, Delcayre C, Hamon M, Lablanche JM, Bertrand ME, Dupis B, Swynghedauw B: Proto-oncogene expression in rabbit aorta after wall injury: first marker of the cellular process leading to restenosis after angioplasty? Eur Heart J 1992, 13:556-559.
14. Moggio RA, Ding JZ, Smith CJ, Tota RR, Stemerman MB, Reed GE: Immediate-early gene expression in human saphenous veins harvested during coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1995, 110:209-213.
15. Clowes AW, Reidy MA, Clowes MM: Kinetics of cellular proliferation after arterial injury. Lab Invest 1983, 49:327-333.
16. Francis SE, Hunter S, Holt CM, Gadsdon PA, Rogers S, Duff GW, Newby AC, Angelini GD: Release of platelet-drived growth factor activity from pig venous arterial grafts. J Thor Cardiovasc Surg 1994, 108:540-548.
17. Hoch JR, Stark VK, Turnipseed WD: The temporal relationship between the development of vein graft intimal hyperplasia and growth factor gene expression. J Vasc Surg 1995, 22:51-58.
18. Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, Kaneda Y, Ogihara T, Dzau VJ: Evidence for direct local effect of angiotensin in vascular hypertrophy: in vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1994, 94:978-984.
19. Morishita R, Gibbons GH, Horiuchi M, Ellison K, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ: A gene therapy strategy using transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 1995, 22:5855-5859.
20. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD: Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992, 359:67-70.
21. DeGregori J, Kowalik T, Nevins JR: Cellular targets for activation by the E2F1 transcription factor include DNA synthesis and G1/S-regulatory genes. Mol Cell Biol 1995, 15:4215-4224.
22. Chen S-J, Wilson JM, Muller DWM: Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circ 1994, 89:1922-1928.
23. Kupfer JM, Ruam XM, Liu G, Matloff J, Forrester J, Chaux A: High efficiency gene transfer to autologous rabbit jugular vein grafts using adenovirus-transferrin/polylysine-DNA complexes. Hum Gene Ther 1994, 5:1437-1443.